Despite the high prevalence of cholesterol screening and awareness, only ≈50% of US adults with familial hypercholesterolemia (FH) are on statin therapy, with even fewer prescribed a high-intensity statin. Researchers used data from the 1999 to 2014 National Health and Nutrition Examination Survey to estimate prevalence rates of self-reported screening, awareness, and statin therapy among US adults (n=42,471 weighted to represent 212 million US adults) with FH and with severe dyslipidemia (defined as low-density lipoprotein cholesterol [LDL-C] levels ≥190 mg/dL). They found:
- The frequency of cholesterol screening and awareness was high (>80%) among adults with definite/probable FH or severe dyslipidemia.
- However, statin use was uniformly low (52.3%) in adults with definite/probable FH and 37.6% in adults with severe dyslipidemia.
- Only 30.3% of patients with definite/probable FH on statins were taking a high-intensity statin.
- Young and uninsured patients are at the highest risk for lack of screening and for undertreatment.
Bucholz EM, Rodday AM, Kolor K, Khoury MJ, de Ferranti SD. Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familiar hypercholesterolemia or other forms of severe dyslipidemia (1999-2014). [Published online ahead of print March 26, 2018]. Circulation. doi:10.1161/CIRCULATIONAHA.117.032321.
This Week's Must Reads
Sex Differences & Tx Goals in Systemic Hypertension, Am J Cardiol; ePub 2018 Jun 22; Ochoa-Jimenez, et al
Effects of Binge Drinking on BP Levels in Young Adults, J Am Heart Assoc; ePub 2018 Jun 27; Piano, et al
Renal Function & Exercise Training in HF Patients, Am J Cardiol; ePub 2018 Jun 23; Ambrosy, et al
Is Poor Sleep a Risk Factor for AF?, Heart Rhythm; ePub 2018 Jun 25; Christensen, et al
2017 ACC/AHA BP Guideline Impact on Stroke Survivors, J Am Heart Assoc; ePub 2018 Jun 6; Lekoubou, et al
Must Reads in Hypercholesterolemia
Racial Differences in Statin Use, JAMA Cardiol; ePub 2018 Jun 13; Nanna, et al
LLT Use in Patients with Elevated LDL-C, Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al
Evolocumab in Differing Patient Populations , J Pharmacokinet Pharmacodyn; ePub 2018 May 7; Kuchimanchi, et al
LDL-C Targets in Elderly Statin Users After ACS, J Am Heart Assoc; ePub 2018 May 12; Alter, et al
Patient Perspectives on Statin Therapy, Clin Cardiol; ePub 2018 May 10; Brinton